Sales of Bod Science’s MediCabilis CBD product range fell sharply during the first half of FY23 with the company attributing the decline to the rising demand for THC flower. Medicinal cannabis revenue slipped 29% to A$578,000 while the firm shifted 37% fewer units between July and December. Despite the disappointing performance, Bod said it was holding its share of the CBD market and was “reviewing opportunities to grow the total addressable market”, including the launch of a CBG product in Australia.
Source: cannabis AND australia – Google Alert